Presented and held a Q&A session on the differentiated competitiveness of the ANGel platform at the Chungbuk Bio Round, hosted by the Chungbuk Center for Creative Economy & Innovation
Differentiated Competitiveness of the ANGel Platform
▶ Overcomes the immunosuppressive environment challenges of existing immuno-oncology therapies.
▶ Reduces the frequency of drug administration, enhancing patient convenience and therapeutic efficacy.
▶ Leverages its technology foundation for further research, enabling global technology transfers and fostering diverse partnerships.